Effect of Postmenopausal Hormone Therapy on Glucose and Insulin Concentrations
Mark Andrew Espeland, Patricia E. Hogan, Samuel Edwin Fineberg et al. · Diabetes Care · 1998
OBJECTIVE: To characterize the long-term impact of four hormone therapy regimens on insulin and glucose concentrations measured during a standard oral glucose tolerance test. RESEARCH DESIGN AND METHODS: The Postmenopausal Estrogen/Progestin Intervention Study was a 3-year placebo-controlled randomized trial to assess effects of four hormone regimens on cardiovascular risk factors. This efficacy analysis describes glucose and insulin concentrations from 788 adherent women at baseline and at 1 and 3 years' postrandomization. RESULTS: When compared with women taking placebo, those taking conjugated equine estrogen (CEE) at 0.625 mg/day with or without a progestational agent had mean fasting insulin levels that were 16.1% lower, mean fasting glucose levels 2.2 mg/dl lower, and mean 2-h glucose levels 6.4 mg/dl higher (each nominal P < 0.05). No significant differences were apparent between women taking CEE only versus the three progestin regimens: medroxyprogesterone acetate (MPA) at 2.5 mg daily (continuous MPA), MPA at 10 mg on days 1-12 (cyclical MPA), and micronized progesterone (MP) (cyclical) at 200 mg on days 1-12. The impact of hormone therapy on insulin and glucose depended on baseline levels of fasting insulin and 1-h glucose (P < 0.05). However, the treatment effects on carbohydrate metabolism appeared to be consistent across participant subgroups formed by lifestyle, clinical, and demographic characteristics. CONCLUSIONS: Oral hormone therapy involving 0.625 mg/day of CEE may modestly decrease fasting levels of insulin and glucose. Postchallenge glucose concentrations are increased, however, which may indicate delayed glucose clearance.
Cited by 239 works. doi:10.2337/diacare.21.10.1589
Authors
- Mark Andrew Espeland
- Patricia E. Hogan
- Samuel Edwin Fineberg
- George Howard
- Helmut G. Schrott
- Myron A. Waclawiw
- Trudy L. Bush
References
- Statistical Analysis With Missing Data
- Immunoassay of Insulin: Two Antibody System: Plasma Insulin Levels of Normal, Subdiabetic and Diabetic Rats
- Controversy in Counting and Attributing Events in Clinical Trials
- Determination of Glucose in Blood Using Glucose Oxidase with an Alternative Oxygen Acceptor
- Fundamentals of Clinical Trials
- Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr
- Unbalanced Repeated-Measures Models with Structured Covariance Matrices
- Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women
- Modeling the Drop-Out Mechanism in Repeated-Measures Studies
- Controversies and achievements in clinical trials